drugset / Trial / NCT04895046
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
Phase II, single arm trial, evaluating molecularly selected, immune-based combination therapy in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the homologous recombination deficient (HRD) signature.
Timeline
- Start
- 2021-10-11
- Primary completion
- 2022-09
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | 500 mg | Intravenous |
| Subject | Dostarlimab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Niraparib | Small molecule | 300 mg | Oral |